Ruxolitinib: A new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis

Future Oncology

Volumn 7, Issue 9, 2011, Pages 1035-1043

  Ostojic, Alen ^a   Vrhovac, Radovan ^a   Verstovsek, Srdan ^b  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

JAK2 inhibitor; JAK2V617F mutation; myelofibrosis; ruxolitinib

Indexed keywords

CYTOKINE; ERYTHROMYCIN; PLACEBO; RIFAMPICIN; RUXOLITINIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANXIETY; APOPTOSIS; ARTICLE; ASTHENIA; CELL PROLIFERATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; MALE; MAXIMUM TOLERATED DOSE; MYELOFIBROSIS; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SPLENOMEGALY; THROMBOCYTOPENIA; URINARY TRACT INFECTION; WEIGHT GAIN;

HUMANS; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; TREATMENT OUTCOME;

EID: 80052994848     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.81     Document Type: Article

References (56)

1. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk. Lymphoma 7(3), 251-255 (1992).
2. Dougan LE, Matthews ML, Armstrong BK. The effect of diagnostic review on the estimated incidence of lymphatic and hematopoietic neoplasms in Western Australia. Cancer 48(3), 866-872 (1981). (Pubitemid 11075249)
3. Johansson P, Kutti J, Andreasson B et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J. Intern. Med. 256(2), 161-165 (2004). (Pubitemid 38998263)
4. Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol. Biol. (Paris) 49(2), 164-166 (2001). (Pubitemid 32242397)
5. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted county study, 1976-1995. Am. J. Hematol. 61(1), 10-15 (1999). (Pubitemid 29218171)
6. Woodliff HJ, Dougan L. Myelofibrosis in Western Australia: an epidemiological study of 29 cases. Med. J. Aust. 1(15), 523-525 (1976).
7. Alvarez-Larran A, Cervantes F, Bellosillo B et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofbrosis in 126 patients. Leukemia 21(6), 1218-1223 (2007). (Pubitemid 46831811)
8. Harrison CN, Campbell PJ, Buck G et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353(1), 33-45 (2005). (Pubitemid 41007805)
9. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 89(7), 2319-2327 (1997). (Pubitemid 27143278)
10. Najean Y, Rain JD, Dresch C et al. Risk of leukaemia, carcinoma, and myelofibrosis in 32P-or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the study of polycythaemias". Leuk. Lymphoma 22(Suppl. 1), 111-119 (1996). (Pubitemid 26388540)
11. Passamonti F, Rumi E, Arcaini L et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 93(11), 1645-1651 (2008).
12. Randi ML, Barbone E, Fabris F, Varotto L, Macri C, Girolami A. Post-polycythemia myeloid metaplasia: experience with a large cohort of patients. J. Med. 25(6), 363-369 (1994).
13. Wolanskyj A P, Schwager SM, Mcclure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo. Clin. Proc. 81(2), 159-166 (2006). (Pubitemid 43205767)
14. Ihle JN, Kerr IM. JAKs and STATs in signaling by the cytokine receptor superfamily. Trends. Genet. 11(2), 69-74 (1995).
15. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J. Cell. Sci. 117(Part 8), 1281-1283 (2004). (Pubitemid 38559804)
16. Barosi G, Bergamaschi G, Marchetti M et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110(12), 4030-4036 (2007). (Pubitemid 350248459)
17. V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22(4), 756-761 (2008). (Pubitemid 351559282)
18. Tefferi A, Lasho TL, Schwager SM et al. The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br. J. Haematol. 131(3), 320-328 (2005). (Pubitemid 43899664)
19. Quintas-Cardama A, Vaddi K, Liu P et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15), 3109-3117 (2010). □□ Published report on the preclinical studies of ruxolitinib.
20. Pardanani AD, Levine RL, Lasho T et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108(10), 3472-3476 (2006).
21. Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3(7), E270 (2006).
22. Oh ST, Simonds EF, Jones C et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116(6), 988-992 (2010).
23. Grand FH, Hidalgo-Curtis CE, Ernst T et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113(24), 6182-6192 (2009).
24. Barbui T, Barosi G, Birgegard G et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol. 29(6), 761-770 (2011).
25. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95(7), 2226-2233 (2000). (Pubitemid 30167718)
26. Rambaldi A. Therapy of myelofibrosis (excluding JAK2 inhibitors). Int. J. Hematol. 91(2), 180-188 (2010).
27. Arana-Yi C, Quintas-Cardama A, Giles F et al. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 11(8), 929-943 (2006). (Pubitemid 44373766)
28. Passamonti F, Cervantes F, Vannucchi AM et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9), 1703-1708 (2010).
29. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464), 1054-1061 (2005). (Pubitemid 40386783)
30. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037), 1144-1148 (2005). (Pubitemid 40663494)
31. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352(17), 1779-1790 (2005). (Pubitemid 40570926)
32. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4), 387-397 (2005). (Pubitemid 40544655)
33. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat. Rev. Drug Discov. 10(2), 127-140 (2011). □ Excellent review of JAK inhibitors currently in different stages of development.
34. Hedvat M, Huszar D, Herrmann A et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16(6), 487-497 (2009).
35. Tyner JW, Bumm TG, Deininger J et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115(25), 5232-5240 (2010).
36. Verstovsek S, Odenike O, Scott B et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or postessential thrombocythemia/polycythemia vera myelofibrosis. Blood 114(22), 3905 (2009).
37. Verstovsek S, Kantarjian H, Mesa RA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363(12), 1117-1127 (2010). □□ Published report on the Phase I/II clinical trial of ruxolitinib.
38. Tefferi A, Kantarjian HM, Pardanani AD et al. The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2. The 50th ASH meeting, San Francisco, CA, USA. Blood 112(11), 2804 (2008) (Abstract).
39. Walker K. Inflammation research association - 15th international conference advances in asthma and COPD and other inflammatory diseases. IDrugs 11(12), 863-865 (2008).
40. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93(3), 397-409 (1998). (Pubitemid 28232084)
41. Parganas E, Wang D, Stravopodis D et al. JAK2 is essential for signaling through a variety of cytokine receptors. Cell 93(3), 385-395 (1998). (Pubitemid 28232083)
42. Fridman J, Nussenzveig R, Liu P et al. Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders. The 49th ASH meeting, Atlanta, GA, USA. Blood 110(11), 3538 (2007) (Abstract).
43. Shilling AD, Nedza FM, Emm T et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab. Dispos. 38(11), 2023-2031 (2010). □□ Report on the pharmacokinetics of ruxolitinib.
44. Chen X, Shi J, Mcgee R et al. The effect of various degrees of hepatic dysfunction on the pharmacokinetics of INCB018424. The 111th ASCPT meeting, Atlanta, GA, USA. Clin. Pharmacol. Ther. 87(Suppl. 1), PIII-59 (2010) (Abstract).
45. Shi J, Chen X, Mcgee R et al. Effects of various degrees of renal impairment and hemodialisis on the pharmacokinetics and pharmacodynamics of INCB018424. The 111th ASCPT meeting, Atlanta, GA, USA. Clin. Pharmacol. Ther. 87(Suppl. 1), PII-53 (2010) (Abstract).
46. Shi J, Chen X, Yeleswaram S et al. An openlabel assessment of the effects of rifampin, a potent CYP3A4 inducer on the PK/PD of INCB018424 in healthy subjects. The 38th ACCP meeting, San Antonio, TX, USA. J. Clin. Pharmacol. 49(9), 9 (2009) (Abstract).
47. Shi J, Chen X, Yeleswaram S et al. An openlabel assessment of the effects of CYP3A4 inhibitors on the PK/PD of INCB018424 in healthy subjects. The 38th ACCP meeting, San Antonio, TX, USA. J. Clin. Pharmacol. 49(9), 10 (2009) (Abstract).
48. Shi JG, Chen X, Emm T et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J. Clin. Pharmacol. DOI:10.1177/0091270011405663 (2011) (Epub ahead of print).
49. Shi JG, Chen X, Mcgee RF et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J. Clin. Pharmacol. DOI: 10.1177/0091270010389469 (2011) (Epub ahead of print).
50. Verstovsek S, Mesa R, Gotlib J et al. Results of COMFORT-I, a randomized double-blind Phase III trial of JAK1/2 inhibitor INCB18424 (424) vs placebo (PB) for patients with myelofibrosis (MF). The 47th ASCO Meeting. Chicago, IL, USA. J. Clin. Oncol. (2011) (Abstract 6500).
51. Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13), 2895-2901 (2009).
52. Mesa RA, Schwager S, Radia D et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk. Res. 33(9), 1199-1203 (2009).
53. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-oflife instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85(5), 365-376 (1993). (Pubitemid 23073154)
54. Verstovsek S, Passamonti F, Rambaldi A et al. A Phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. Presented at: The 51st ASH Meeting. New Orleans, LA, USA. Blood 114(22), 311 (2009) (Abstract).
55. Williams W, Scherle P, Shi J et al. A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Presented at: The 72nd ACR Meeting. San Francisco, CA, USA, 714 (2008) (Abstract).
56. Callis Duffin K, Luchi M, Fidelus-Gort R et al. Novel mechanism for topical treatment of plaque psoriasis - results of a randomized, double blind, concentration ranging, vehicle controlled 12 week study with JAK 1/2 inhibitor INCB018424 cream. The 70th SID meeting, Atlanta, GA, USA. J. Invest. Dermatol. 130(Suppl. 1), 261 (2010) (Abstract).